STAT+: HHS green lights six peptides, despite concerns from FDA scientists — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- HHS issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides without fear of federal enforcement.
- BPC-157 and TB-500 are among the six compounds and are described as a popular injury-recovery duo.
- FDA career scientists objected to the HHS policy, saying there is scant evidence that the substances are safe or effective.
- Trump administration is giving the peptide craze a regulatory boost through the HHS policy, even as FDA career scientists object.
Why it matters: Licensed pharmacies and physicians gain a temporary route to compound six experimental peptides without federal enforcement, while FDA career scientists say evidence of safety and effectiveness is scant. The material divide is access versus proof: HHS authorizes enforcement relief for six compounds even as FDA scientists question their evidentiary basis.
Ask SkimNews
